IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Zacks News
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.
Cutera, NetEase, West Pharmaceutical, IDEXX Laboratories and Align Tech highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Cutera, NetEase, West Pharmaceutical, IDEXX Laboratories and Align Tech highlighted as Zacks Bull and Bear of the Day
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Bet on These 3 MedTech Growth Stocks for 2021 & Beyond
by Riya Anand
Stocks like West Pharmaceutical Services (WST), IDEXX Laboratories (IDXX) and Align Technology (ALGN) make great picks for the long term.
Here's Why You Should Retain Globus Medical (GMED) for Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) owing to domestic growth in the spine business and robust demand for the HEDRON line of products.
Here's Why You Should Retain Walgreens (WBA) Stock for Now
by Zacks Equity Research
Investors are optimistic about Walgreens (WBA), given the strong performance in the International segment and notable product launches.
Here's Why You Should Retain Inogen (INGN) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
PacBio (PACB) Closes Omniome Buyout, Forays Into San Diego
by Zacks Equity Research
PacBio's (PACB) latest acquisition is expected to deliver a differentiated set of products and applications across a wide spectrum of markets.
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.
PerkinElmer (PKI) to Benefit From BioLegend Buyout: Here's How
by Zacks Equity Research
PerkinElmer's (PKI) latest acquisition is likely to expand its life science business and enhance its reagents portfolio.
Thermo Fisher (TMO) Introduces New Automated Enzyme Analyzers
by Zacks Equity Research
The two new Gallery Enzyme Master systems by Thermo Fisher (TMO) offer enhanced reliable enzyme analysis across several enterprises.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and solid global performance.
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for EXKIVITY
by Zacks Equity Research
Thermo Fisher (TMO) gains FDA pre-market approval for Oncomine Dx as companion diagnostic for Takeda's EXKIVITY.
Here's Why You Should Retain Catalent (CTLT) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.
Accuray's (ARAY) CyberKnife Favored For Prostate Cancer Treatment
by Zacks Equity Research
Per the PACE trial data, patients treated with Accuray's (ARAY) CyberKnife SBRT are likely to experience lesser bladder-related side effects unlike conventional linear accelerator.
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval From MHLW
by Zacks Equity Research
Thermo Fisher's (TMO) Oncomine Dx Target Test has been approved by MHLW as a companion diagnostic for Eli Lilly and Company's selpercatinib.
Dexcom's (DXCM) G6 CGM Under NIHB Program to Aid More Patients
by Zacks Equity Research
Expanded access to Dexcom's (DXCM) G6 CGM for clients enrolled in NIHB is expected to aid a wider patient pool to better manage their diabetes.
Here's Why You Should Retain CONMED (CNMD) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
Here's Why You Should Retain Allscripts (MDRX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.
NextGen's (NXGN) RCM Services Adopted by Coastal Orthopedics
by Zacks Equity Research
NextGen's (NXGN) RCM Services aids Coastal Orthopedics to maintain its financial stability throughout the pandemic period.
NextGen (NXGN) Reaches 2 Million Telehealth Visit Milestone
by Zacks Equity Research
NextGen (NXGN) reaches a milestone by facilitating 2 million telehealth visits with the NextGen Virtual Visits platform since March 2020.
Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
Reasons to Hold on to AMN Healthcare (AMN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
SmileDirectClub (SDC) Struggles With New Markets, High Debt
by Zacks Equity Research
SmileDirectClub's (SDC) escalating costs and expenses are putting pressure on the bottom line.
Stryker (SYK) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Stryker's (SYK) strength in robotics and its diversified product portfolio.